Clarity Pharmaceuticals Ltd
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CU6.AX research report →
Price Chart
About the company
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceuticals products for oncology in Australia and the United States. The company’s lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic radiopharmaceutical to treat prostate, breast, ovarian, urinary, small cell lung cancer, as well as glioblastoma and gastrointestinal stromal tumours; and SARTATE, a theranostic radiopharmaceutical for the treatment of somatostatin receptor 2 (SSTR2) cancer.
- CEO
- Michelle Parker
- IPO
- 2021
- Employees
- 88
- HQ
- Sydney, NSW, AU
Get TickerSpark's AI analysis on CU6.AX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $925.24M
- P/E
- -8.86
- Fwd P/E
- 7.12
- PEG
- 0.16
- P/S
- 193.79
- P/B
- 3.88
- EV/EBITDA
- -8.42
- Div Yield
- 0.00%
- Gross Margin
- 96.85%
- Op Margin
- -2131.42%
- Net Margin
- -2015.88%
- ROE
- -59.59%
- ROIC
- -41.42%
Latest fiscal year · YoY change
- Revenue
- $9.46M-17.8%
- Gross Profit
- $9.46M-17.8%
- Op Income
- $-69,094,025
- Net Income
- $-64,295,435-51.9%
- EPS
- $-0.20-33.3%
- OCF Growth
- -26.7%
- FCF Growth
- -25.6%
- 52W High
- $5.87
- 52W Low
- $1.80
- 50D MA
- $2.37
- 200D MA
- $2.98
- Beta
- 1.18
- RSI (14)
- 48
- Avg Volume
- 2.73M
No earnings-call transcripts are available for CU6.AX yet.
- Free Float
- 61.5%
- Shares Outstanding
- 373.08M
- Float Shares
- 229.60M
Held by 92 ETFs
Biggest fund positions in CU6.AX by dollar value.
Our CU6.AX coverage
Recent articles, reports, and earnings notes.
No research on CU6.AX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CU6.AX report →Co-PSMA: Cu-64 SAR-bisPSMA more than doubled prostate cancer lesion and patient detection vs. Ga-68 PSMA-11 in head-to-head trial
prnewswire.com · Feb 16
Co-PSMA abstract accepted for oral presentation at EAU Annual Congress 2026
prnewswire.com · Dec 24
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.